Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib + Quercetin in early Alzheimer's disease
NCT04063124Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Feb 2020
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, quercetin in Alzheimer's disease (AD), sponsored by UT Health San Antonio. Started Feb 2020; status: completed.
02
Drugs
dasatinibquercetin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04063124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04063124.